Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The envelope glycoprotein (Env) of the feline immunodeficiency virus (FIV) is a critical viral protein responsible for mediating the entry of the virus into host cells. Like other lentiviruses, FIV encodes a single Env precursor that is cleaved into two non-covalently associated subunits: the surface glycoprotein (SU, also known as gp95) and the transmembrane glycoprotein (TM, also known as gp35). The SU binds first to CD134 on target cells—a primary receptor unique to FIV among lentiviruses, then engages CXCR4 as a coreceptor. After receptor engagement, conformational changes in TM mediate fusion between viral and cellular membranes—enabling viral entry. Variable regions within SU—especially V3 and V5 loops—are key determinants for coreceptor usage and immune evasion.
N/A - Target for entry inhibitors (hypothetical)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Feline Immunodeficiency Virus Envelope Glycoprotein (FIV Env).